Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy

References

• Trotter CL, Chandra M, Cano R et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol. Rev.31(1), 27–36 (2007).
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases. Prevention of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics116(2), 496–505 (2005).
   PubMed Web of Science ®Google Scholar
• Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.54(RR-7), 1–21 (2005).
   PubMedGoogle Scholar
• Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N. Engl. J. Med.344(18), 1378–1388 (2001).
   PubMed Web of Science ®Google Scholar
• Mond JJ, Kokai-Kun JF. The multifunctional role of antibodies in the protective response to bacterial T cell-independent antigens. Curr. Top. Microbiol. Immunol.319, 17–40 (2008).
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay ME. Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine20(Suppl. 1), S58–S67 (2001).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices. Revised recommendations of the Advisory Committee on Immunization Practices to Vaccinate all persons aged 11–18 years with meningococcal conjugate vaccine. MMWR Morb. Mortal. Wkly Rep.56(31), 794–795 (2007).
   PubMedGoogle Scholar
• National Advisory Committee on Immunization (NACI). Statement on conjugate meningococcal vaccine for serogroups A, C, Y, and W135. Can. Commun. Dis. Rep. Wkly33(ACS-3), 1–24 (2007).
   Google Scholar
• Rennels M, King J Jr, Ryall R, Papa T, Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr. Infect. Dis. J.23(5), 429–435 (2004).
   PubMed Web of Science ®Google Scholar
• Snape MD, Perrett KP, Ford KJ et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA299(2), 173–184 (2008).
   PubMed Web of Science ®Google Scholar
• Boisier P, Nicolas P, Djibo S et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin. Infect. Dis.44(5), 657–663 (2007).
   PubMed Web of Science ®Google Scholar
• Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr. Infect. Dis. J.23(12 Suppl.), S274–S279 (2004).
   PubMedGoogle Scholar
• Molesworth AM, Thomson MC, Connor SJ et al. Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa. Trans. R. Soc. Trop. Med. Hyg.96(3), 242–249 (2002).
   PubMed Web of Science ®Google Scholar
• WHO. Enhanced surveillance of epidemic meningococcal meningitis in Africa: a three-year experience. Wkly Epidemiol. Rec.80(37), 313–320 (2005).
   PubMedGoogle Scholar
• Russell JE, Urwin R, Gray SJ, Fox AJ, Feavers IM, Maiden MC. Molecular epidemiology of meningococcal disease in England and Wales 1975–1995, before the introduction of serogroup C conjugate vaccines. Microbiology154(Pt 4), 1170–1177 (2008).
   PubMed Web of Science ®Google Scholar
• Peltola H, Jónsdóttir K, Lystad A, Sievers CJ, Kallings I. Meningococcal disease in Scandinavia. Br. Med. J. (Clin. Res. Ed.)284(6329), 1618–1621 (1982).
   PubMed Web of Science ®Google Scholar
• Patel MS, Merianos A, Hanna JN et al. Epidemic meningococcal meningitis in central Australia, 1987–1991. Med. J. Aust.158(5), 336–340 (1993).
   PubMed Web of Science ®Google Scholar
• Riou JY, Caugant DA, Selander RK, Poolman JT, Guibourdenche M, Collatz E. Characterization of Neisseria meningitidis serogroup A strains from an outbreak in France by serotype, serosubtype, multilocus enzyme genotype and outer membrane protein pattern. Eur. J. Clin. Microbiol. Infect. Dis.10(5), 405–409 (1991).
   PubMed Web of Science ®Google Scholar
• Zhang X, Shao Z, Zhu Y et al. Genetic characteristics of serogroup A meningococci circulating in China, 1956–2005. Clin. Microbiol. Infect.14(6), 555–561 (2008).
   PubMed Web of Science ®Google Scholar
• Achtman M, van der Ende A, Zhu P et al. Molecular epidemiology of serogroup A meningitis in Moscow, 1969 to 1997. Emerg. Infect. Dis.7(3), 420–427 (2001).
   PubMed Web of Science ®Google Scholar
• Salleras L, Dominguez A, Cardenosa N. Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine. Vaccine21, 729–733 (2003).
   PubMed Web of Science ®Google Scholar
• Dickinson FO, Pérez AE. Bacterial meningitis in children and adolescents: an observational study based on the national surveillance system. BMC Infect. Dis.5, 103 (2005).
   PubMed Web of Science ®Google Scholar
• Holst J, Feiring B, Naess LM et al. The concept of “tailor-made”, protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine23(17–18), 2202–2205 (2005).
   PubMed Web of Science ®Google Scholar
• O’Hallahan J, Lennon D, Oster P. The strategy to control New Zealand’s epidemic of group B meningococcal disease. Pediatr. Infect. Dis. J.23(Suppl. 12), S293–S298 (2004).
   Google Scholar
• Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989–1991. MMWR CDC Surveill. Summ.42(2), 21–30 (1993).
   PubMedGoogle Scholar
• Antignac A, Ducos-Galand M, Guiyoule A, Pirès R, Alonso JM, Taha MK. Neisseria meningitidis strains isolated from invasive infections in France (1999–2002): phenotypes and antibiotic susceptibility patterns. Clin. Infect. Dis.37(7), 912–920 (2003).
   Google Scholar
• von Gottberg A, du Plessis M, Cohen C et al.; Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa. Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa. Clin. Infect. Dis.46(3), 377–386 (2008).
   PubMed Web of Science ®Google Scholar
• Nathan N, Rose AM, Legros D et al. Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg. Infect. Dis.13(6), 920–923 (2007).
   PubMed Web of Science ®Google Scholar
• Taha MK, Achtman M, Alonso JM et al. Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet356(9248), 2159 (2000).
   PubMed Web of Science ®Google Scholar
• Materu S, Cox H, Isaakidis P, Baruani B, Ogario T, Caugant DA. Serogroup X in meningococcal disease outbreak, Western Kenya [letter]. Emerg. Infect. Dis.13(6), 944–945 (2007).
   PubMed Web of Science ®Google Scholar
• Cartwright KA, Stuart JM, Jones DM, Noah ND. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol. Infect.99, 591–601 (1987).
   PubMed Web of Science ®Google Scholar
• Gold R, Goldschneider I, Lepow ML, Draper TF, Randolph M. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J. Infect. Dis.137(2), 112–121 (1978).
   PubMed Web of Science ®Google Scholar
• Claus H, Maiden MC, Wilson DJ et al. Genetic analysis of meningococci carried by children and young adults. J. Infect. Dis.191(8), 1263–1271 (2005).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Greenwood BM. Meningococcal carriage in the African meningitis belt. Lancet Infect. Dis.7(12), 797–803 (2007).
   PubMed Web of Science ®Google Scholar
• Yazdankhah SP, Kriz P, Tzanakaki G et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J. Clin. Microbiol.42(11), 5146–5153 (2004).
   PubMed Web of Science ®Google Scholar
• Maiden MC, Stuart JM; UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet359(9320), 1829–1831 (2002).
   PubMed Web of Science ®Google Scholar
• Ala’Aladeen DA, Neal KR, Ait-Tahar K et al. Dynamics of meningococcal long term carriage among university students and their implications for mass vaccination. J. Clin. Microbiol.38(6), 2311–2316 (2000).
   PubMed Web of Science ®Google Scholar
• Blakebrough IS, Greenwood BM, Whittle HC, Bradley AK, Gilles HM. The epidemiology of infections due to Neisseria meningitidis and Neisseria lactamica in a northern Nigerian community. J. Infect. Dis.146(5), 626–637 (1982).
   PubMed Web of Science ®Google Scholar
• MacLennan J, Kafatos G, Neal K et al.; United Kingdom Meningococcal Carriage Group. Social behavior and meningococcal carriage in British teenagers. Emerg. Infect. Dis.12(6), 950–957 (2006).
   PubMed Web of Science ®Google Scholar
• Bogaert D, Hermans PW, Boelens H et al. Epidemiology of nasopharyngeal carriage of Neisseria meningitidis in healthy Dutch children. Clin. Infect. Dis.40(6), 899–902 (2005).
   PubMed Web of Science ®Google Scholar
• Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA286(6), 688–693 (2001).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Barkham TM, Earnest A, Paton NI. Acquisition of W135 meningococcal carriage in Hajj pilgrims and transmission to household contacts: prospective study. BMJ325, 365–366 (2002).
   PubMed Web of Science ®Google Scholar
• Neal KR, Nguyen-Van-Tam JS, Jeffrey N et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BMJ320(7238), 846–849 (2000).
   PubMed Web of Science ®Google Scholar
• Tyski S, Grzybowska W, Dulny G, Berthelsen L, Lind I. Phenotypical and genotypical characterization of Neisseria meningitidis carrier strains isolated from Polish recruits in 1998. Eur. J. Clin. Microbiol. Infect. Dis.20(5), 350–353 (2001).
   PubMed Web of Science ®Google Scholar
• Simmons G, Martin D, Stewart J, Jones N, Calder L, Bremner D. Carriage of Neisseria meningitidis among household contacts of patients with meningococcal disease in New Zealand. Eur. J. Clin. Microbiol. Infect. Dis.20(4), 237–242 (2001).
   PubMed Web of Science ®Google Scholar
• Bakir M, Yagci A, Ulger N, Akbenlioglu C, Ilki A, Soyletir G. Asymtomatic carriage of Neisseria meningitidis and Neisseria lactamica in relation to Streptococcus pneumoniae and Haemophilus influenzae colonization in healthy children: apropos of 1400 children sampled. Eur. J. Epidemiol.17(11), 1015–1018 (2001).
   PubMed Web of Science ®Google Scholar
• Moore PS, Hierholzer J, Dewitt W et al. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA264(10), 1271–1275 (1990).
   PubMed Web of Science ®Google Scholar
• Stuart JM, Cartwright KA, Dawson JA, Rickard J, Noah ND. Risk factors for meningococcal disease: a case control study in south west England. Community Med.10, 139–146 (1988).
   PubMedGoogle Scholar
• Pace D, Pollard AJ. Meningococcal A, C, Y and W-135 polysaccharide–protein conjugate vaccines. Arch. Dis. Child.92(10), 909–915 (2007).
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med.129(6), 1307–1326 (1969).
   PubMed Web of Science ®Google Scholar
• Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J. Exp. Med.129, 1367–1384 (1969).
   PubMed Web of Science ®Google Scholar
• Reingold AL, Broome CV, Hightower AW et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet2(8447), 114–118 (1985).
   PubMed Web of Science ®Google Scholar
• Granoff DM, Pollard AJ. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr. Infect. Dis. J.26(8), 716–722 (2007).
   PubMed Web of Science ®Google Scholar
• Dellicour S, Greenwood B. Systematic review: impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop. Med. Int. Health12(12), 1409–1421 (2007).
   PubMed Web of Science ®Google Scholar
• Peltola H, Safary A, Käyhty H, Karanko V, Andre FE. Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides. Pediatrics76, 91–96 (1985).
   PubMed Web of Science ®Google Scholar
• Lepow ML, Beeler J, Randolph M, Samuelson JS, Hankins WA. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J. Infect. Dis.154, 1033–1036 (1986).
   PubMed Web of Science ®Google Scholar
• Gold R, Lepow ML, Goldschneider I, Draper TL, Gotschlich EC. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J. Clin. Invest.56(6), 1536–1547 (1975).
   PubMed Web of Science ®Google Scholar
• Armand J, Arminjon F, Mynard MC, Lefaix C. Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serologic evaluation. J. Biol. Stand.10, 335–339 (1982).
   PubMedGoogle Scholar
• Rosenstein N, Levine O, Taylor JP et al. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA279(6), 435–439 (1998).
   PubMed Web of Science ®Google Scholar
• Bilukha O, Messonnier N, Fischer M. Use of meningococcal vaccines in the United States. Pediatr. Infect. Dis. J.26(5), 371–376 (2007).
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A. Meningococcal disease: risk for international travellers and vaccine strategies. Travel. Med. Infect. Dis.6(4), 182–186 (2008).
   PubMedGoogle Scholar
• MacLennan J, Obara S, Deeks J et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunization during early childhood. Vaccine17(23–24), 3086–3093 (1999).
   PubMed Web of Science ®Google Scholar
• Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J. Infect. Dis.178, 870–874 (1998).
   PubMed Web of Science ®Google Scholar
• Al-Mazrou Y, Khalil M, Borrow R et al. Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age. Infect. Immun.73(5), 2932–2939 (2005).
   PubMed Web of Science ®Google Scholar
• Keyserling H, Papa T, Koranyi K et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch. Pediatr. Adolesc. Med.159(10), 907–913 (2005).
   PubMed Web of Science ®Google Scholar
• Chippaux JP, Garba A, Ethevenaux C et al. Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C–diphtheria toxoid conjugate vaccine in infants in Niger. Vaccine22(25–26), 3303–3311 (2004).
   PubMed Web of Science ®Google Scholar
• Lee CH, Kuo WC, Beri S et al. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine27(5), 726–732 (2009).
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years. Vaccine27(1), 161–168 (2009).
   PubMed Web of Science ®Google Scholar
• Bardotti A, Averani G, Berti F et al. Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases. Vaccine26(18), 2284–2296 (2008).
   PubMed Web of Science ®Google Scholar
• Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Schneider H, Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N. Engl. J. Med.282(8), 417–420 (1970).
   PubMed Web of Science ®Google Scholar
• Wahdan MH, Rizk F, el-Akkad AM et al. A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull. World Health Organ.48(6), 667–673 (1973).
   PubMed Web of Science ®Google Scholar
• WHO. Requirements for meningococcal polysaccharide vaccine. World Health Organization technical report series, no.594. WHO, Geneva, Switzerland (1976).
   Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection – serum bactericidal antibody activity. Vaccine23(17–18), 2222–2227 (2005).
   PubMed Web of Science ®Google Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol.10(5), 780–786 (2003).
   PubMedGoogle Scholar
• Zollinger WD, Mandrell RE. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun.40(1), 257–264 (1983).
   PubMed Web of Science ®Google Scholar
• Balmer P, Borrow R. Issues surrounding standardization of meningococcal group W135 serology. Vaccine25(Suppl. 1), A63–A68 (2007).
   Google Scholar
• Heath PT, Booy R, Azzopardi HJ et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA284(18), 2334–2340 (2000).
   PubMed Web of Science ®Google Scholar
• Rennels MB, Edwards KM, Keyserling HL et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics101(4 Pt 1), 604–611 (1998).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet364(9431), 365–367 (2004).
   PubMed Web of Science ®Google Scholar
• Halperin SA, Diaz-Mitoma F, Anemona A, Ceddia FC. Safety and immunogenicity of Novartis Vacines MenACWY conjugate vaccine after one or two doses administered to infants and young children. Presented at: The 5th World Congress of the World Society for Pediatric Infectious Diseases (WSPID). Bangkok, Thailand, 15–18 November 2007.
   Google Scholar
• Perrett KP, Snape MD, Ford KJ et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr. Infect. Dis. J.28(3), 186–193 (2009).
   PubMed Web of Science ®Google Scholar
• Black S, Dull P. MenACWY–CRM, a novel quadrivalent meningococcal conjugate vaccine, is well tolerated and immunogenic in infancy through adolescence. Presented at: The 26th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Graz, Austria, 13–17 May 2008.
   Google Scholar
• Vesikari T, Ceddia F, Karvonen A, Anemona A, Danzig L, Schmitt HJ. Immune response and immunological memory induced by a novel meningococcal ACWY-CRM conjugate vaccine (MenACWY) in toddlers. Presented at: The23rd Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID). Valencia, Spain, 18–20 May 2005.
   Google Scholar
• Black S, Shah J, Danzig L et al. Safety and immunogenicity 12 months post-vaccination with Novartis Vaccines’ tetravalent glycoconjugate meningococcal ACWY vaccine in children aged 2–10 years. Presented at: The 45th Annual meeting of the Infectious Diseases Society of America (IDSA). CA, USA, 4–7 October 2007.
   Google Scholar
• Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr. Infect. Dis. J.28(2), 86–91 (2009).
   PubMed Web of Science ®Google Scholar
• Jackson L, Baxter R, Reisinger K, Shah J, Bedell L, Dull PM. A Phase III study comparing the safety and immunogenicity of a novel quadrivalent meningococcal conjugate vaccine, MenACWY–CRM, with the licensed MCV4, Menactra, in adolescents. Presented at: The Pediatric Academic Societies (PAS) Annual Meeting. Honolulu, HA, 3–6 May 2008.
   Google Scholar
• Gasparini R, Conversano M, Bona G et al. Immunogenicity and safety of MenACWY–CRM, a novel quadrivalent meningococcal conjugate vaccine, administered concomitantly with Tdap in healthy subjects 11–25 years of age. Presented at: The 26th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Graz, Austria, 13–17 May 2008.
   Google Scholar
• Dull PM, Shah L, Bedell A, Anemona A, Karsten A. MenACWY-CRM, a novel quadrivalent meningococcal conjugate vaccine, is well tolerated and immunogenic in infants through adolescents. Presented at: The 16th International Pathogenic Neisseria Conference (IPNC). Rotterdam, The Netherlands, 7–12 September 2008.
   Google Scholar
• Arguedas A, Soley C, Loaiza C et al. Safety and immunogenicity of MenACWY-CRM administered sequentially or concomitantly with Tdap and HPV vaccines. Presented at: The 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th Annual meeting. Washington, DC, USA, 25–28 October 2008.
   Google Scholar
• Arguedas A, Soley C, Loaiza C et al. Reactogenicity of MenACWY–CRM administered sequentially or concomitantly with Tdap and HPV vaccines. Presented at: 2nd Vaccine Congress. Boston, MA, USA, 7–9 December 2008.
   Google Scholar
• Booy R, Jelfs J, El Bashir H, Nissen MD. Impact of meningococcal C conjugate vaccine use in Australia. Med. J. Aust.186(3), 108–109 (2007).
   PubMed Web of Science ®Google Scholar
• de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in The Netherlands. Pediatr. Infect. Dis. J.25(1), 79–80 (2006).
   PubMed Web of Science ®Google Scholar
• Snape MD, Kelly DF, Lewis S et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ336(7659), 1487–1491 (2008).
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2–10 years with quadrivalent meningococcal conjugate vaccine (MCV4). MMWR Morb. Mortal. Wkly Rep.57(17), 462–465 (2008).
   PubMedGoogle Scholar
• LaForce FM, Konde K, Viviani S, Préziosi MP. The Meningitis Vaccine Project. Vaccine25(Suppl. 1), A97–A100 (2007).
   PubMed Web of Science ®Google Scholar